D. Scott Neal’s Alexion Pharmaceuticals ALXN Stock Holding History

D. Scott Neal’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,200	Closed	-$149K	–	68
2018 Q2	$149K	Hold	1,200	–	–	0.08%	45
2018 Q1	$134K	Hold	1,200	–	–	0.08%	52
2017 Q4	$144K	Hold	1,200	–	–	0.09%	53
2017 Q3	$168K	Hold	1,200	–	–	0.1%	43
2017 Q2	$146K	Sell	1,200 -800	-40%	-$93.1K	0.1%	56
2017 Q1	$242K	Hold	2,000	–	–	0.16%	37
2016 Q4	$245K	Hold	2,000	–	–	0.17%	32
2016 Q3	$245K	Hold	2,000	–	–	0.19%	27
2016 Q2	$234K	Hold	2,000	–	–	0.21%	29
2016 Q1	$278K	Hold	2,000	–	–	0.26%	27
2015 Q4	$382K	Hold	2,000	–	–	0.3%	24
2015 Q3	$313K	Hold	2,000	–	–	0.26%	27
2015 Q2	$362K	Hold	2,000	–	–	0.25%	29
2015 Q1	$347K	Hold	2,000	–	–	0.25%	27
2014 Q4	$370K	Hold	2,000	–	–	0.26%	28
2014 Q3	$332K	Hold	2,000	–	–	0.26%	28
2014 Q2	$313K	Hold	2,000	–	–	0.25%	30
2014 Q1	$304K	Hold	2,000	–	–	0.26%	36
2013 Q4	$266K	Buy	+2,000	New	+$240K	0.24%	31

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

D. Scott Neal's ALXN Position: Q3 2018 in Review

D. Scott Neal sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 1,200 shares — an estimated $149K sold.

D. Scott Neal first reported a position in ALXN in Q4 2013 and held it in 19 quarters. The position peaked at $382K in Q4 2015. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

D. Scott Neal reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
D. Scott Neal sold 1,200 Alexion Pharmaceuticals shares in Q3 2018, an estimated $149K.
D. Scott Neal first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 19 quarters.
D. Scott Neal's Alexion Pharmaceuticals position peaked at $382K in Q4 2015.
585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on D. Scott Neal's 13F filing for Q3 2018, filed 13 Nov 2018.